Gilead Sciences, Inc. $GILD Shares Sold by Lbp Am Sa

Key Points

• Lbp Am Sa reduced its stake in Gilead Sciences by 29.1%, holding 145,594 shares valued at approximately $16.14 million after selling 59,711 shares during the second quarter.
• Analysts have set new price targets for Gilead Sciences, with JPMorgan Chase raising their target from $135 to $145 and several firms upgrading their ratings, contributing to an average price target of $117.17.
• Gilead recently declared a quarterly dividend of $0.79 per share, resulting in an annualized yield of 2.8%, with a payout ratio of 62.95%.

Lbp Am Sa trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 29.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 145,594 shares of the biopharmaceutical company's stock after selling 59,711 shares during the period. Lbp Am Sa's holdings in Gilead Sciences were worth $16,142,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC grew its stake in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock worth $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on GILD. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a report on Tuesday, August 19th. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 16th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Finally, UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Stock Down 1.4%

Gilead Sciences stock opened at $111.00 on Wednesday. The stock's 50 day moving average price is $114.52 and its 200 day moving average price is $109.91. Gilead Sciences, Inc. has a 1-year low of $82.82 and a 1-year high of $121.83. The company has a market cap of $137.73 billion, a PE ratio of 22.11, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the prior year, the company posted $2.01 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.